Drug Type TCR-T Cell therapy |
Synonyms Autologous CD4+/CD8+ T cells transduced with lentiviral vector directed against MAGE-A4 antigen, KSH 01, KSH01 |
Target |
Action inhibitors |
Mechanism MAGEA4 inhibitors(Melanoma-associated antigen 4 inhibitors), Cell replacements |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhaseEarly Phase 1 |
First Approval Date- |
RegulationOrphan Drug (United States) |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Bladder Cancer | Phase 1 | China | 11 Oct 2022 | |
| Esophageal Carcinoma | Phase 1 | China | 11 Oct 2022 | |
| Melanoma | Phase 1 | China | 11 Oct 2022 | |
| Stomach Cancer | Phase 1 | China | 11 Oct 2022 | |
| Advanced Malignant Solid Neoplasm | Phase 1 | China | 19 Aug 2022 | |
| Liver Cancer | Phase 1 | China | 19 Aug 2022 | |
| Relapsed Solid Neoplasm | Phase 1 | China | 19 Aug 2022 |





